AKERO THERAPEUTICS INC. - COMMON STOCK

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

28 فبراير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

30 يناير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

28 يناير 2025 21:30:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Announces Proposed Public Offering of Common Stock

27 يناير 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

27 يناير 2025 06:30:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

24 يناير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

13 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

26 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

15 نوفمبر 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

13 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

08 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

21 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

30 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

09 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

28 أغسطس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

09 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

11 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

08 يونيو 2024 08:15:00 بحسب Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

29 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire